top of page
  • Recruiting
    • Dec 16, 2011

NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With RRMM Myeloma

NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

Carfilzomib Multiple Myeloma Expanded Access Protocol

NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease



The purpose of this study is to expand upon the safety data for carfilzomib by providing expanded access to patients with relapsed and refractory multiple myeloma who are unable to enroll in any other ongoing carfilzomib trial.


Sponsor

Amgen


Collaborator

Multiple Myeloma Research Foundation


 

ClinicalTrials.gov Identifier: NCT01410500

Official Title: Carfilzomib Multiple Myelom